50 Chapter 2 Table e-3. Clinical progression in three ATN categories in SCD Details clinical progression Cox proportional hazard models N Total, n (%) MCI, n AD, n Other dementia, n Progression to dementia¤ Progression to MCI or dementia¤ Normal AD biomarkers 175 9 (5%) 7 0 2 1 (reference) 1 (reference) Non-AD pathologic change 90 6 (7%) 2 2 2 3.2 (0.617.8) 0.9 (0.32.6) Alzheimer’s continuum 77 31 (40%) 15 14 2 17.0 (3.679.0) 7.5 (3.416.5) ¤: Cox proportional hazard models, adjusted for age, sex and education. Data is presented as Hazard Ratio (HR) (95% CI). MCI=mild cognitive impairment; AD=Alzheimer’s disease Table e-4. Relationship between ATN categories and baseline and longitudinal cognition in three ATN categories in SCD Baseline Longitudinal Non-AD pathologic change Alzheimer’s continuum Non-AD pathologic change Non-AD pathologic change VAT-A -0.05 (0.08) -0.12 (0.09) -0.12 (0.09) -0.54 (0.08)* RAVLT immediate recall 0.90 (0.79) -1.15 (0.95) -1.15 (0.95) -2.16 (0.45)* RAVLT delayed recall 0.16 (0.26) -0.86 (0.31)* -0.86 (0.31)* -0.75 (0.14)* Digit span forward 0.23 (0.25) 0.32 (0.30) 0.32 (0.30) -0.10 (0.08) Digit span backward 0.41 (0.22) 0.26 (0.27) 0.26 (0.27) -0.22 (0.09)* Animal fluency 0.45 (0.50) 0.07 (0.60) 0.07 (0.60) -0.68 (0.22)*
RkJQdWJsaXNoZXIy MjY0ODMw